Gabriel N. Hortobágyi

6 ta ish

The University of Texas MD Anderson Cancer Center

1. Prognostic Value of Pathologic Complete Response After Primary Chemotherapy in Relation to Hormone Receptor Status and Other Factors

   Valentina Guarneri, Kristine Broglio, Shu‐Wan Kau +8

   Maqola20063 iqtibos

   ABIABI:AkademIndex/2026.other.434434

2. Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer

   Mark Ayers, W. Fraser Symmans, James Stec +15

   Maqola20043 iqtibos

   ABIABI:AkademIndex/2026.other.434439

3. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

   Roman Rouzier, Charles M. Perou, W. Fraser Symmans +13

   Maqola20053 iqtibos

   ABIABI:AkademIndex/2026.other.434441

4. Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

   Gabriel N. Hortobágyi

   Maqola20123 iqtibos

   ABIABI:AkademIndex/2026.other.434442

5. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

   Cornelia Liedtke, Chafika Mazouni, Kenneth R. Hess +10

   Maqola20233 iqtibos

   ABIABI:AkademIndex/2026.other.434446

6. Role of epidermal growth factor receptor in breast cancer

   Hiroko Masuda, Dongwei Zhang, Chandra Bartholomeusz +3

   Sharh maqola20122 iqtibos

   ABIABI:AkademIndex/2026.other.464571